MedTrace Logo

Safety and Efficacy of IDP-122 Lotion When Applied Topically to Subjects With Moderate to Severe Plaque Psoriasis

NCT02785185 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2020-08-27

Study results available
· View outcomes & findings →

Summary

A Phase 2, Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study.

Conditions

Interventions

DRUG

IDP-122 Vehicle Lotion

Vehicle

DRUG

IDP-122 Vehicle Cream

Vehicle

DRUG

IDP-122 Lotion

Lotion

DRUG

Ultravate Cream

Cream

Sponsors & Collaborators

  • Bausch Health Americas, Inc.

    lead INDUSTRY

Principal Investigators

  • Binu J Alexander, MD · Valeant Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2016-12-02
Completion
2017-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02785185 on ClinicalTrials.gov